Search | IOVS | ARVO Journals

Showing 1 – 20 of 175

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina March 2025

Addressing Multiplicity in Retinal Sensitivity Analysis: An Alternative Approach to Assessing Gene Therapy Efficacy in Inherited Retinal Diseases

PDF

Antonio Yaghy; David G. Birch; Yunchan Hwang; Edmund Luo; JungAh Jung; Darin Curtiss; Nadia K. Waheed
TAGS: gene therapy, retinal diseases, sensitivity analysis, treatment effect
Trans. Vis. Sci. Tech.. 2025; 14(3):25. https://doi.org/10.1167/tvst.14.3.25

Perspective December 2024

Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs

PDF

Jacque L. Duncan; Angela Bowman; Amy Laster; Claire Gelfman; David G. Birch; Shannon E. Boye; Stephen P. Daiger; Lucian del Priore; Donald J. Zack; James T. Handa; the Foundation Fighting Blindness Scientific Advisory Board
TAGS: age-related macular degeneration, genes, genetics, retinal degeneration, disease progression, gene therapy, vision, medical management, blindness
Trans. Vis. Sci. Tech.. 2024; 13(12):28. https://doi.org/10.1167/tvst.13.12.28

Retina October 2024

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

PDF

Maureen G. Maguire; David G. Birch; Jacque L. Duncan; Allison R. Ayala; Lauren N. Ayton; Janet K. Cheetham; Peiyao Cheng; Todd A. Durham; Frederick L. Ferris, III; Carel B. Hoyng; Rachel M. Huckfeldt; Glenn J. Jaffe; Christine Kay; Eleonora M. Lad; Bart P. Leroy; Wendi Liang; Lee S. McDaniel; Michele Melia; Michel Michaelides; Mark E. Pennesi; José-Alain Sahel; Lassana Samarakoon; on behalf of the REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: cohort studies, eye, natural history, outcome measures, retinal degeneration, sample size, surrogate endpoints, vision, united states food and drug administration, perimetry
Trans. Vis. Sci. Tech.. 2024; 13(10):15. https://doi.org/10.1167/tvst.13.10.15

Includes: Supplemental Content

ARVO Imaging in the Eye Conference Abstract July 2024

Method of Applying Deep Learning Model (DLM) Trained on OCT Images of Lower Axial Resolution to Images of Higher Axial Resolution without Model Retraining for Retinal Layer Segmentation

Yi-Zhong Wang; Mark E. Pennesi; Siyu Chen; David G. Birch

Invest. Ophthalmol. Vis. Sci.. 2024; 65(9):PB0013.

ARVO Annual Meeting Abstract June 2024

Impact of Training Dataset Size on Deep Learning Model’s Performance of Measuring Photoreceptor Outer Segment Metrics in Patients with Retinitis Pigmentosa (RP)

Yi-Zhong Wang; Katherine Juroch; David G Birch

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3743.

ARVO Annual Meeting Abstract June 2024

Baseline structural and functional findings from a PRPH2(p.Gly208Asp) natural history study

Rasha kako; Fritz Gerald Paguiligan Kalaw; Evan Walker; Naomi E. Wagner; Shaden Yassin; Ines Nagel; David G Birch; Borooah Shyamanga

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6668.

ARVO Annual Meeting Abstract June 2024

SD-OCT Features and Macular Sensitivity in ABCA4 -related Stargardt disease (STGD1)

Yanzhao WANG; Folahan Adesola Ibukun; Elias Traboulsi; David G Birch; Janet S Sunness; Rupert Strauss; Isabelle S Audo; Michel Michaelides; SriniVas R Sadda; Hendrik P Scholl; Eberhart Zrenner; Michael S Ip; Artur V Cideciyan; Paul S Bernstein; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):975.

ARVO Annual Meeting Abstract June 2024

Longitudinal structure-function (S-F) relationship between short-wavelength autofluorescence (SW-FAF) and macular sensitivity (MS) in ABCA4 -associated Stargardt (STGD1) disease

Folahan Adesola Ibukun; Yanzhao Wang; Artur V Cideciyan; David G Birch; Janet S Sunness; Isabelle S Audo; Michel Michaelides; Elias Traboulsi; SriniVas R Sadda; Michael S Ip; Hendrik P Scholl; Rupert Strauss; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3350.

ARVO Annual Meeting Abstract June 2024

Spatial and anatomic parameters from SD-OCT and associations with best corrected visual acuity (BCVA) in ABCA4-associated Stargardt Disease (STGD1)

Xiangrong Kong; Yanzhao WANG; Folahan Adesola Ibukun; David G Birch; Elias Traboulsi; Janet S Sunness; Paul S Bernstein; Isabelle S Audo; Michel Michaelides; SriniVas R Sadda; Hendrik P Scholl; Eberhart Zrenner; Michael S Ip; Sheila K West; Artur V Cideciyan; Rupert Strauss

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2374.

ARVO Annual Meeting Abstract June 2024

Subretinal gene therapy AGTC-501 for X-linked retinitis pigmentosa in the Phase 1/2 Horizon study: Post-hoc analysis of microperimetry results in the high dose groups

David G Birch; Andreas K Lauer; Paul Yang; Robert Sisk; Rajiv Anand; Darin Curtiss; Amy Christenson; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2133.

ARVO Annual Meeting Abstract June 2024

OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations

Byron L Lam; Arun K Upadhyay; Shankar Musunuri; Murthy Chavali; Sahar Matloob; Nalin Mehta; David G Birch; Paul Yang; Benjamin Bakall; Nieraj Jain; Jose S. Pulido; Borooah Shyamanga

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):406.

ARVO Annual Meeting Abstract June 2024

A Phase 1 First in Human Study of VP-001; a peptide conjugate of oligonucleotide designed to treat Retinitis Pigmentosa Type 11 patients

Fred Chen; David G Birch; Carla Jackson; Anna Mills; Laura Florez; Jessica Nichols; Paula Cunningham; Janya Grainok; Adam Martin; Subrata Das; Sue Fletcher; Clare Guerrero; Sri Mudumba

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1024.

ARVO Annual Meeting Abstract June 2024

Progressive vision loss related to sexual dimorphism in retinitis pigmentosa

Ashley Rowe; Tiffany Yee; Emily Nettesheim; David G Birch; Katherine J. Wert

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4894.

ARVO Annual Meeting Abstract June 2024

PRPH2 Gene Mutations and Associated Phenotypes in IRD patients with diverse genetic background.

Christopher Hallock; Riccardo Sangermano; Elfride De Baere; Siying Lin; Jennifer Thompson; Pascal Escher; Andrea L Vincent; Kaylie D Webb-Jones; Monika Grudzinska Pechhacker; Jacque L Duncan; Samer Khateb; Tamar Ben-Yosef; David G Birch; Andrew Webster; Radha Ayyagari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5297.

Retina November 2023

Deep Learning–Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR -Related X-Linked Retinitis Pigmentosa

PDF

Yi-Zhong Wang; Katherine Juroch; Yineng Chen; Gui-Shuang Ying; David G. Birch
TAGS: deep learning, photoreceptors, retinitis pigmentosa, volume, x-linked inheritance, eye, baseline value, follow-up, disease progression
Invest. Ophthalmol. Vis. Sci.. 2023; 64(14):31. https://doi.org/10.1167/iovs.64.14.31

Perspective June 2023

Overcoming the Challenges to Clinical Development of X-Linked Retinitis Pigmentosa Therapies: Proceedings of an Expert Panel

PDF

David G. Birch; Janet K. Cheetham; Stephen P. Daiger; Carel Hoyng; Christine Kay; Ian M. MacDonald; Mark E. Pennesi; Lori S. Sullivan
TAGS: gene therapy, mutation, natural history, phenotype, retinitis pigmentosa, x-linked inheritance, disease progression, blindness, retinal diseases, surrogate endpoints
Trans. Vis. Sci. Tech.. 2023; 12(6):5. https://doi.org/10.1167/tvst.12.6.5

ARVO Annual Meeting Abstract June 2023

The Pro-EYS study: Baseline microperimetry, ellipsoid zone area, and central subfield retinal thickness

David G Birch

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4654.

ARVO Annual Meeting Abstract June 2023

Impact of High-Risk Features Associated with AMD Progression on Retinal Sensitivity

Houri Esmaeilkhanian; Muneeswar Gupta Nittala; Swetha B Velaga; David G Birch; Dwight Stambolian; SriniVas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):296.

ARVO Annual Meeting Abstract June 2023

Deep Learning Facilitated Study of the Rate of Change in Photoreceptor Outer Segment (OS) Metrics in X-Linked Retinitis Pigmentosa (xlRP)

Yi-Zhong Wang; Katherine Juroch; Yineng Chen; Gui-Shuang Ying; David G Birch

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4640.

ARVO Annual Meeting Abstract June 2023

Sensitivity of Confrontation Visual Fields in Detecting Field Loss Due to Retinitis Pigmentosa

Lauren Payne; David G Birch

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1469.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Addressing Multiplicity in Retinal Sensitivity Analysis: An Alternative Approach to Assessing Gene Therapy Efficacy in Inherited Retinal Diseases

Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

Method of Applying Deep Learning Model (DLM) Trained on OCT Images of Lower Axial Resolution to Images of Higher Axial Resolution without Model Retraining for Retinal Layer Segmentation

Impact of Training Dataset Size on Deep Learning Model’s Performance of Measuring Photoreceptor Outer Segment Metrics in Patients with Retinitis Pigmentosa (RP)

Baseline structural and functional findings from a PRPH2(p.Gly208Asp) natural history study

SD-OCT Features and Macular Sensitivity in ABCA4 -related Stargardt disease (STGD1)

Longitudinal structure-function (S-F) relationship between short-wavelength autofluorescence (SW-FAF) and macular sensitivity (MS) in ABCA4 -associated Stargardt (STGD1) disease

Spatial and anatomic parameters from SD-OCT and associations with best corrected visual acuity (BCVA) in ABCA4-associated Stargardt Disease (STGD1)

Subretinal gene therapy AGTC-501 for X-linked retinitis pigmentosa in the Phase 1/2 Horizon study: Post-hoc analysis of microperimetry results in the high dose groups

OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations

A Phase 1 First in Human Study of VP-001; a peptide conjugate of oligonucleotide designed to treat Retinitis Pigmentosa Type 11 patients

Progressive vision loss related to sexual dimorphism in retinitis pigmentosa

PRPH2 Gene Mutations and Associated Phenotypes in IRD patients with diverse genetic background.

Deep Learning–Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR -Related X-Linked Retinitis Pigmentosa

Overcoming the Challenges to Clinical Development of X-Linked Retinitis Pigmentosa Therapies: Proceedings of an Expert Panel

The Pro-EYS study: Baseline microperimetry, ellipsoid zone area, and central subfield retinal thickness

Impact of High-Risk Features Associated with AMD Progression on Retinal Sensitivity

Deep Learning Facilitated Study of the Rate of Change in Photoreceptor Outer Segment (OS) Metrics in X-Linked Retinitis Pigmentosa (xlRP)

Sensitivity of Confrontation Visual Fields in Detecting Field Loss Due to Retinitis Pigmentosa

To View More...

You must be signed into an individual account to use this feature.